Pfizer Plans to Launch Remicade Biosimilar in November
October 17 2016 - 6:40PM
Dow Jones News
Pfizer Inc. plans to start U.S. shipments of biosimilar
Inflectra, its copycat version of Johnson & Johnson's
anti-inflammatory drug Remicade, at a 15% discount to Remicade's
wholesale prices starting in late November.
Pfizer, which has U.S. commercialization rights to Inflectra,
said the estimated wholesale price doesn't include discounts to
payers, distributors and others.
Inflectra, developed by South Korea pharmaceutical company
Celltrion Inc., received Food and Drug Administration approval
earlier this year but faced legal challenges over a patent for
Remicade.
Inflectra, the second approved biosimilar treatment in the U.S.,
is approved to treat rheumatoid arthritis, ulcerative colitis and
Crohn's disease.
Write to Tess Stynes at tess.stynes@wsj.com
(END) Dow Jones Newswires
October 17, 2016 18:25 ET (22:25 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024